170 related articles for article (PubMed ID: 36808341)
1. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
Pawlak-Buś K; Schmidt W; Leszczyński P
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
[TBL] [Abstract][Full Text] [Related]
2. [Low disease activity and remission status of systemic lupus erythematosus in a real-world study].
Ren L; Zhao C; Zhao Y; Zhou H; Zhang L; Wang Y; Shen L; Fan W; Li Y; Li X; Wang J; Cheng Y; Peng J; Zhao X; Shao M; Li R
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):273-278. PubMed ID: 38595244
[TBL] [Abstract][Full Text] [Related]
3. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
Golder V; Kandane-Rathnayake R; Huq M; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337
[TBL] [Abstract][Full Text] [Related]
5. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
[TBL] [Abstract][Full Text] [Related]
6. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Pitsigavdaki S; Nikoloudaki M; Garantziotis P; Silvagni E; Repa A; Marangoni A; Flouri I; Avgoustidis N; Parperis K; Fanouriakis A; Govoni M; Sidiropoulos P; Boumpas DT; Bortoluzzi A; Bertsias G
Ann Rheum Dis; 2024 Mar; 83(4):464-474. PubMed ID: 38233103
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers JO; Genre F; Hiepe F; Gerosa M; Kovács L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; ; Alarcón-Riquelme ME; Beretta L
Ann Rheum Dis; 2024 Jun; 83(7):889-900. PubMed ID: 38373843
[TBL] [Abstract][Full Text] [Related]
8. Targeting DORIS Remission and LLDAS in SLE: A Review.
Parra Sánchez AR; van Vollenhoven RF; Morand EF; Bruce IN; Kandane-Rathnayake R; Weiss G; Tummala R; Al-Mossawi H; Sorrentino A
Rheumatol Ther; 2023 Dec; 10(6):1459-1477. PubMed ID: 37798595
[TBL] [Abstract][Full Text] [Related]
9. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.
Tani C; Elefante E; Signorini V; Zucchi D; Lorenzoni V; Carli L; Stagnaro C; Ferro F; Mosca M
RMD Open; 2019; 5(2):e000916. PubMed ID: 31275608
[TBL] [Abstract][Full Text] [Related]
11. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.
Tani C; Vagelli R; Stagnaro C; Carli L; Mosca M
Lupus Sci Med; 2018; 5(1):e000234. PubMed ID: 29531772
[TBL] [Abstract][Full Text] [Related]
12. Remission in SLE-do DORIS criteria match the treating physician's judgment? A cross-sectional study to assess reasons for discordance.
Mucke J; Düsing C; Klose N; Schneider M; Chehab G
Rheumatology (Oxford); 2021 Sep; 60(9):4298-4305. PubMed ID: 33493321
[TBL] [Abstract][Full Text] [Related]
13. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
[TBL] [Abstract][Full Text] [Related]
14. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus.
Na Nakorn K; Piyaphanee N; Sukharomana M; Pinpatanapong R; Charuvanij S
Clin Rheumatol; 2023 Jun; 42(6):1655-1664. PubMed ID: 36780064
[TBL] [Abstract][Full Text] [Related]
16. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
[TBL] [Abstract][Full Text] [Related]
17. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
[TBL] [Abstract][Full Text] [Related]
18. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
Abdelhady EI; Rabie M; Hassan RA
Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
[TBL] [Abstract][Full Text] [Related]
19. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Petri M; Magder LS
Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
